News|Articles|November 18, 2026

2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD

Author(s)Leah Kuntz
Listen
0:00 / 0:00

Key Takeaways

  • OPTI-101 will be evaluated as single-dose psilocybin monotherapy versus active placebo in 200 adults with severe MDD, with identical psychological support and antidepressant discontinuation pre-dose.
  • The phase 2b primary endpoint is MADRS change at week 3 via independent blinded central raters, with week 6 as an alternative and functional/disability outcomes assessed through week 12.
SHOW MORE

Learn more about the randomized, double-blind phase 2b study of naturally derived psilocybin in MDD, and more.

Optimi Health has provided an update on its clinical programs, including OPTI-101 naturally derived psilocybin for major depressive disorder (MDD) and OPTI-201 MDMA for posttraumatic stress disorder (PTSD).

“2027 is a pivotal year for Optimi as we advance several product candidates. Our lead product candidate, OPTI-101, is naturally derived psilocybin already prescribed in Australia, with no serious adverse events reported. Subject to Health Canada approval, we expect to begin dosing in a randomized, blinded phase 2b study, with topline data expected in 2028. OPTI-201 is expected to start phase 3 for veterans and front-line workers, and production of our first ibogaine capsules is weeks away. We are preparing to take these programs to the US Food and Drug Administration,” said JJ Wilson, the chairman of the board.1

OPTI-101 for MDD

OPTI-101 is a capsule of naturally derived psilocybin, being developed as an alternative to synthetic psilocybin; the most advanced psilocybin programs in the United States use synthetic psilocybin. The same naturally derived psilocybin capsule is prescribed commercially in Australia, with clinical and commercial supply sharing one formulation and one Chemistry, Manufacturing and Controls (CMC) file. OPTI-101 is expected to be supported by controlled clinical trial data and real-world evidence from Australia, where it is currently prescribed outside clinical trials for treatment-resistant depression.

In the upcoming phase 2b multi-site, randomized, double-blind, active placebo-controlled trial, a single dose of OPTI-101 psilocybin will be tested against an active placebo in 200 adults with severe MDD and a Montgomery-Åsberg Depression Rating Scale (MADRS) score of 30 or higher, confirmed by a blinded central rater. There will be identical psychological support in both arms. Serotonergic antidepressants will be discontinued before dosing, so OPTI-101 is evaluated as monotherapy.

The primary endpoint is change in MADRS at week 3, assessed by independent central raters blinded to treatment; week 6 is the pre-specified alternative. Key secondary endpoints include change in MADRS at weeks 6 and 12, and in the Sheehan Disability Scale at week 12.

Dosing is expected to start in Q1 2027. Topline data is expected in 2028. Optimi is preparing an IND for the FDA ahead of the planned phase 3 trial for the same indication.

Topline data will include the primary and key secondary endpoints and durability through 6 months, following database lock after the last participant’s week 26 visit. Twelve-month durability data are expected to follow. No interim efficacy analysis is planned.

OPTI-201 for PTSD

OPTI-201, Optimi’s late-stage product candidate, consists of GMP MDMA capsules manufactured in Canada and prescribed for PTSD in Australia. MDMA has been available in Australia since October 2024, and is now positioned to enter the US if MDMA-assisted therapy is approved.

A phase 3 Health Canada-cleared study of 100 veterans and front-line workers—including military, police, paramedics, firefighters and health care workers—with PTSD is expected to initiate in 2027. Participants receive 2 supervised dosing sessions 2 to 3 weeks apart.

Optimi has an IND filing with the FDA planned for 2027, alongside initiation of the Canadian phase 3 study. The primary endpoint is change in Clinician-Administered PTSD Scale (CAPS-5) total severity score from baseline to week 8.
The key secondary endpoint is change in functional impairment.

With MDMA-assisted therapy for PTSD before the FDA, Optimi intends to position OPTI-201 as a potential MDMA alternative in the United States if it is approved, supported by its own phase 3 data and more than 2 years of commercial supply and related data from Australia. The Company plans to file an IND with the FDA for OPTI-201 in 2027.

Ibogaine Initiative

Additionally, Optimi expects to produce its first finished-dose ibogaine capsules in-house in the coming weeks. Optimi is working to make these products available to US ibogaine research funded by the Advanced Research Projects Agency for Health (ARPA-H).

Akin to ketamine, ibogaine’s mechanism entails NMDA receptor antagonism. However, ibogaine and its active metabolite noribogaine interact with other systems, including opioid receptors (μ and κ) and nicotinic acetylcholine receptors.2

References

1. Optimi Health outlines 2027 plans for OPTI-101 phase 2b in major depressive disorder and OPTI-201 phase 3 in PTSD; announces shares-for-debt settlement. News release. November 18, 2026. Accessed November 18, 2026. https://www.globenewswire.com/news-release/2026/11/18/3405552/0/en/optimi-health-outlines-2027-plans-for-opti-101-phase-2b-in-major-depressive-disorder-and-opti-201-phase-3-in-ptsd-announces-shares-for-debt-settlement.html

2. Forcen FE. The top 7 atypical psychedelics: a brief clinical guide. Psychiatric Times. 2026;43(9).


Related to this article